Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Jul-Sep;12(3):153-60.
doi: 10.1007/BF03189891.

Erythromycin lactobionate: pharmacokinetics and uterine tissue levels

Affiliations

Erythromycin lactobionate: pharmacokinetics and uterine tissue levels

A Segui et al. Eur J Drug Metab Pharmacokinet. 1987 Jul-Sep.

Abstract

Erythromycin is well-known for its properties of tissular diffusion. An estimation of its concentration in uterine tissue seemed worthwhile, in order to justify the use of erythromycin lactobionate in uterine infections by sensitive micro-organisms. The authors studied the uterine levels of this macrolid, after perfusion of 1g of erythromycin lactobionate, over a period of one hour. The protocol involved a group of 15 women, who were to undergo a hysterectomy for benign non-inflammatory pathology. The uterine specimens and plasmatic pharmacokinetics of the antibiotic constitute the data. The concentrations of antibiotic were determined by microbiological methods. 2 sets of results emerge: during perfusion, the uterine erythromycin levels are equal or inferior to simultaneous serum levels. after perfusion, the uterine levels are superior to serum levels. A bicompartmental linear model was used, which simulated the tissular levels in standard treatment with erythromycin lactobionate. If the erythromycin 4 micrograms/ml critical concentration is compared with uterine tissue concentration, the antibiotic may be expected to be active against a uterine affected by sensitive micro-organisms during a period of approximately 5 hours. This result must be confirmed by a clinical study.

PubMed Disclaimer

References

    1. J Pharmacokinet Biopharm. 1979 Apr;7(2):127-45 - PubMed
    1. J Pharm Sci. 1968 Jan;57(1):128-33 - PubMed
    1. J Pharm Sci. 1978 Aug;67(8):1057-9 - PubMed
    1. Antimicrob Agents Chemother. 1978 Nov;14(5):723-6 - PubMed